Last reviewed · How we verify
Scalp blocks with ropivacaine and intravenous parecoxib
Scalp blocks with ropivacaine and intravenous parecoxib is a Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved.
At a glance
| Generic name | Scalp blocks with ropivacaine and intravenous parecoxib |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Scalp blocks with ropivacaine and intravenous parecoxib CI brief — competitive landscape report
- Scalp blocks with ropivacaine and intravenous parecoxib updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about Scalp blocks with ropivacaine and intravenous parecoxib
What is Scalp blocks with ropivacaine and intravenous parecoxib?
Scalp blocks with ropivacaine and intravenous parecoxib is a Small molecule drug developed by Beijing Tiantan Hospital.
Who makes Scalp blocks with ropivacaine and intravenous parecoxib?
Scalp blocks with ropivacaine and intravenous parecoxib is developed and marketed by Beijing Tiantan Hospital (see full Beijing Tiantan Hospital pipeline at /company/beijing-tiantan-hospital).
What development phase is Scalp blocks with ropivacaine and intravenous parecoxib in?
Scalp blocks with ropivacaine and intravenous parecoxib is FDA-approved (marketed).